# Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel

> **NCT04079374** · PHASE3 · UNKNOWN · sponsor: **Joint Stock Company "Farmak"** · enrollment: 160 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Etanercept
- **DRUG:** Enbrel

## Key facts

- **NCT ID:** NCT04079374
- **Lead sponsor:** Joint Stock Company "Farmak"
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-03
- **Primary completion:** 2021-12-03
- **Final completion:** 2023-12-03
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2021-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04079374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04079374, "Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04079374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*